Literature DB >> 21839731

LC-MS/MS quantitation of ribavirin in serum and identification of endogenous isobaric interferences.

Darlington Danso1, Loralie J Langman, Christine L H Snozek.   

Abstract

BACKGROUND: Ribavirin is a nucleoside analog used in treatment of chronic hepatitis C. It is associated with severe, dose-dependent toxicities, including hemolytic anemia. To facilitate therapeutic drug monitoring, a liquid chromatography-tandem mass spectrometry method was validated for quantitation of ribavirin in serum.
METHODS: After protein precipitation, ribavirin is quantitated using a (13)C(5)-ribavirin internal standard, on a Hypercarb analytical column designed for retention of polar analytes.
RESULTS: The analytical method shows excellent precision, sensitivity, and specificity. In vitro drug stability was also assessed. Interestingly, endogenous isobaric compounds were noted in both human and bovine serum; these could be chromatographically separated from the ribavirin peak. Addition of exogenous uridine and cytosine increases the size of the isobaric peaks, suggesting that these compounds are the source of the endogenous interference.
CONCLUSIONS: This method uses mass spectrometric transitions that have been used in other published methods, but also separates ribavirin from isobaric peaks that were not described. These peaks were determined to be endogenous nucleosides. Laboratories quantitating ribavirin in biological matrices should be aware of the potential for isobaric interferences, and take steps to chromatographically separate them from the ribavirin peak for accurate quantitation.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839731     DOI: 10.1016/j.cca.2011.07.016

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.

Authors:  Manel Aouri; Darius Moradpour; Matthias Cavassini; Thomas Mercier; Thierry Buclin; Chantal Csajka; Amalio Telenti; Andri Rauch; Laurent A Decosterd
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

2.  Intravenous Ribavirin for Parainfluenza and Respiratory Syncytial Virus in an Infant Receiving Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.

Authors:  Cheryl L Sargel; Mohammed Aboud; Aimee Forster; Loralie J Langman; Jessica Tansmore; Bruce A Mueller; William E Smoyer; Jeffery J Auletta
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

Review 3.  Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Authors:  Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco
Journal:  Talanta       Date:  2020-11-05       Impact factor: 6.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.